|Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast|
A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five minutes prior to start time. The conference ID number is 11938616. An archived version of the webcast will be available on Infinity's website for 30 days.
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Investor Relations and Corporate Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infinity-announces-the-date-of-its-first-quarter-2017-financial-results-conference-call-and-webcast-300445393.html